Objective: To assess the incidence rate and severity of depressive symptoms in different time points (12, 24 and 48 weeks) in Brazilian patients with HCV treated with PEG IFN plus ribavirin.
IntroductIon
Chronic hepatitis C is a major public health problem. About 150 million people are chronically infected with hepatitis C virus (HCV), and more than 350 000 people die every year from hepatitis C-related liver diseases. 1 The HCV is commonly transmitted through exposure to infected blood, through the receipt of contaminated blood transfusions, blood products and organ transplants, and usage of contaminated syringes.
Combined therapy with pegylated interferon (PEG IFN) and ribavirin is the mainstay of hepatitis C treatment; 1 however, a high incidence of depressive symptoms is associated with the treatment with IFN [2] [3] [4] [5] [6] , which, in addition to the burden of psychiatric illness itself, causes a negative impact on both treatment adherence and quality of life. 3, 7, 8 Early diagnosis and treatment of depression are associated with better adherence to antiviral therapy; 3 therefore, practical diagnosis and assessment tools are useful in non-psychiatric medical settings, in order to adequately treat this disorder.
The BDI has two subscales: somatic and affective. The affective subscale contains eight items: pessimism, past failures, guilt feelings, punishment feelings, self-dislike, selfcriticalness, suicidal thoughts or wishes, and worthlessness. The somatic subscale consists of the other thirteen items: sadness, loss of pleasure, crying, agitation, loss of interest, indecisiveness, loss of energy, change in sleep patterns, irritability, change in appetite, concentration difficulties, tiredness and/or fatigue, and loss of interest in sex. 9 The CES-D scale is a short self-report scale designed to measure depres-sive symptoms in the general population. The items of the scale are symptoms associated with depression which have been used in previously validated longer scales. 10 Some authors state that neurovegetative symptoms (e.g. fatigue, psychomotor slowing, changes in sleep and appetite) tend to occur early in treatment and persist, whilst more depression-specific symptoms (e.g. loss of interest or pleasure, depressed mood) develop later during therapy 11 . Accordingly, we have also measured the correlation between somatic subscales and the overall scale scores.
methodS
The present study aims at measuring the incidence rate of depressive symptoms in a sample of 50 HCV--infected patients treated with pegylated interferon alpha (PEG IFN) plus ribavirin, in different time points, comparing pre-treatment with 12, 24 and 48 weeks of treatment, using the Beck Depression Inventory (BDI) 9 and the Center for Epidemiologic Studies Depression Scale (CES-D). 10 We also assessed whether premorbid conditions, such as substance abuse and depression, and demographic characteristics (age, gender), were associated with a higher risk of depression. We conducted an observational prospective epidemiologic study with a convenience sample; subjects were consecutively included from April 2007 to February 2009. All the subjects were eligible to therapy with PEG IFN plus ribavirin and were under treatment at the Gastroenterology Outpatient Service, Gafrée and Guinle University Hospital, Rio de Janeiro, Brazil. The inclusion criteria of this study therefore represent the requirements to be submitted to treatment with PEG IFN plus ribavirin in our institution. The study was approved by the Gafrée and Guinle University Hospital Ethics Committee, and it was conducted in accordance with the Declaration of Helsinki (1975 Helsinki ( , revised in 1989 . All the patients signed an informed consent before any data was collected. Since this was an observational study, all the patients followed their routine treatment, and any drug treatment, including use of antidepressant, was dictated by the judgment of treating physicians.
Inclusion criteria:
HCV infection, detected by the presence of HCV RNA, by polymerase chain reaction (Amplicor ® , Roche Diagnostics, Branchburg, NJ, USA) for more than 6 months;
• Age > 18 years old;
• Stable hepatic disease (serum bilirubin < 1.5 g/dL, RNI <1.5, serum albumin >3.4 g/dL, platelets >75,000 cells/mm 3 and absence of ascites and hepatic encephalopathy);
• Biochemistry and hematological parameters: creatinin <1.5 mg/dL, hemoglobin >13 g/dL for men and > 12 g/ dL for women, neutrophil count > 1,500 cells/mm 3 .
Exclusion criteria
• Co-infection with HIV;
• Co-infection with Hepatitis B virus (HBV);
• Presence of hepatocellular carcinoma;
• Substance and/or alcohol abuse in the last 6 months;
• Use of psychotropic medication in the last 6 months, including antidepressants, benzodiazepines, hypnotics, anticonvulsants, mood stabilizers, opioids, antiparkinsonian, antipsychotics and anticholinesterasics; • Diagnosis of depression in the last 6 months.
Pharmacotherapy
All patients were treated with combined PEG IFN alpha--2b (1.5 µg/kg subcutaneously, once weekly) plus ribavirin (750 to 1250 mg/day, per oral). Genotypes 2 and 3 should receive treatment for 6 months and genotype 1 patients should be treated for 12 months.
Assessments
Patients were assessed with interviews using the BDI, version revised in 1979 9, 12 and the CES-D, 10 two self-rated scales, before starting pharmacotherapy, and after 12 and 24 weeks of treatment. An additional interview after 48 weeks was scheduled only for patients with genotype 1. Although the scales were self-rated, the interviewer helped the respondents to make sure they understood the questions, by reading aloud the questions whenever necessary, as there was a high prevalence of illiteracy in our sample. The principal investigator (LPM), physician and well trained in the assessment tool, was the only interviewer.
We chose the BDI and the CES-D as assessment tools because our intention was to assess the depressive symptoms, instead of making a categorical diagnosis of depression; for this purpose, the choice of psychometric tools seemed to be more adequate.
Although our primary aim was to assess the frequency and severity of depressive symptoms, we also measured the incidence rate of PEG IFN-induced depression, considering the CES-D score > 15 (for subjects with CES-D score < 15 before treatment) or an increase of > 1 SD in comparison with the group mean at the moment of the evaluation (for subjects with CES-D > 15 before treatment with PEG IFN). The BDI cut-off adopted for depression was a score > 10 (for patients with score <10 before treatment, i.e., with no depression), or an increase in the mean score indicating a change for a higher level of severity of symptoms (10-18 points = mild to moderate depression; 19-29 = moderate to severe depression and 30-63= severe depression). 13 
Statistics
The SPSS (Statistical Package for the Social Sciences) version 13 was used for analyses. Fischer exact test was used to compare categorical variables. Friedman test and Wilcoxon test (Bonferroni corrected) were performed to compare mean depressive symptoms in distinct time points; Spearman correlation coefficient was used to assess correlations between subscales and overall scale scores; c 2 McNemar test was performed to compare the correlation between BDI and CES-D. We included in the analyses the data of all patients while they remained under treatment.
Results from different time points were compared after Bonferroni correction, to adjust the variation in number of subjects throughout the study.
reSultS
Fifty subjects were included. Demography and genotype characteristics are described in Table 1 . By random circumstances, the same proportion of males and females occurred in our sample. The overall mean BDI score before treatment was 6.5 ± 5.3 and the mean CES-D was 10.9 ± 7.8. The total scores of depressive symptoms measured by either BDI or CES-D increased compared to the baseline. The highest scores were observed at week 24, with both CES-D and BDI (Table 2) , regardless of the genotype.
One patient abandoned treatment due to depression with psychotic symptoms, which did not remit with antidepressant and antipsychotic drugs. After 12 weeks, 2 patients were considered treatment failure and interrupted the antiviral treatment. After 24 weeks, other 11 patients were considered treatment failure and stopped antiviral treatment.
The overall incidence rate of PEG IFN-induced depression was 64% (N= 32) with BDI and 52% (N= 26) with CES-D; 46% (N=23) had PEG IFN-induced depression by either BDI or CES-D. Regarding demographic characteristics, the incidence was similar in males and females, and there was no influence of age or ethnicity; the incidence of PEG IFN-induced depression was higher in subjects with history of alcohol and other substances' abuse (Table 3 ). Higher scores before treatment ("depression positivity") were not predictive of depression during treatment, according to CES-D (p>0.05 in all time points); however, higher BDI scores correlated with depression during PEG IFN treatment (p=0.001 in 12 weeks, p< 0.001 in 24 weeks and p=0.008 in 28 weeks).
The somatic/psychomotor subscale scores were highly correlated with the overall scale scores: Spearman correlation coefficients ranged from 0.831 to 0.955 for CES-D (p<0.001) and from 0.705 to 0.872 for the BDI (p<0.001) in the different time points of the study. CES--D and BDI were also highly correlated, with a Spearman correlation coefficient close to 1 throughout the observation period. pective studies using validated screening tools have shown a high incidence of depression with PEG IFN as well. 3, 5, 19 Presently, there is considerable variability of the frequency and extent of IFN-induced depression reported in different cohorts of patients, due to different study populations, treatment regimens, methodological approaches, arbitrary or poorly defined choice of screening instruments for depression, and different criteria for clinically relevant depression (cut-off criteria). 11 A recent meta-analysis showed that IFN-induced depression is 25% in 24 weeks and 28% in 48 weeks, and the risk factors are: high baseline symptoms level, female gender, low educational level and history of depressive episodes. 20 In our sample, the observed incidence was 46% , with peak of symptoms occurring at week 24. Pavlovic et al. 15 , in a 24-week prospective study, observed the highest score of symptoms at week 12 and also noticed that self-assessment scale was equally reliable as observer-based assessments of depressive symptoms. Although the peak of symptoms in our sample occurred in 24 weeks, at week 12 there was also a significant increase in depressive symptoms compared to the baseline. The use of two scales increased the sensitivity and specificity of the assessments and allowed a comparison with a wider range of data from the literature. Treatment with IFN seems to have an overall impact in all dimensions of depression, as the somatic and mood subscales were equally affected.
Different from other studies, 5, 15, 21 our data showed a correlation between history of substance/alcohol abuse and IFN-induced depression. On the other hand, a correlation with gender and previous depressive episodes was not observed, contrary to findings from other authors. 20 Our study is limited by the small sample size and the lack of a control group. However, it corroborates the data in the literature, and provides additional information regarding development of symptoms and the use of CES-D and BDI as screening and assessment tools. The BDI seems to be more sensitive to changes during treatment period. As depression affects the quality of life and adherence to treatment, 3, 7, 8 it is fundamental to have strategies to deal with this condition. Although prophylaxis of IFN-induced depression with antidepressants remains controversial, 22 pharmacological treatment of depression after its onset has proven effective and beneficial. 3, 23 concluSIonS
In conclusion, there is a high incidence rate of PEG IFN--induced depression and depressive symptoms measured by both BDI and CES-D. The somatic/psychomotor subscales were highly correlated with the overall scale scores. Subjects with history of substance and alcohol abuse had higher risk for IFN-induced depression. 
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